Effects of the APOEɛ4 Allele on the Relationship Between Tau and Amyloid-β in Early- and Late-Onset Alzheimer's Disease.
暂无分享,去创建一个
D. Na | Y. Noh | Seongho Seo | Jeong-Hyeon Shin | N. Okamura | Sang-Yoon Lee | Jae Myeong Kang | Woo-Ram Kim | Ha-Eun Seo | K. Park | J.‐K. Seong
[1] D. Yang,et al. The Seoul Neuropsychological Screening Battery (SNSB) for Comprehensive Neuropsychological Assessment , 2023, Dementia and neurocognitive disorders.
[2] V. Villemagne,et al. Imaging of Reactive Astrogliosis by Positron Emission Tomography , 2022, Frontiers in Neuroscience.
[3] G. Frisoni,et al. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[4] W. Jagust,et al. Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET , 2020, Neurology.
[5] Sheina Emrani,et al. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review , 2020, Alzheimer's Research & Therapy.
[6] Hanna Cho,et al. Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease , 2020, Alzheimer's research & therapy.
[7] S. Gauthier,et al. APOEε4 potentiates the relationship between amyloid-β and tau pathologies , 2020, Molecular Psychiatry.
[8] Muhammad Naveed Iqbal Qureshi,et al. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. , 2019, JAMA neurology.
[9] Paul E. Gilbert,et al. APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia , 2019, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[10] D. Holtzman,et al. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.
[11] T. Südhof,et al. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk , 2019, The Journal of Neuroscience.
[12] K. Bötzel,et al. PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes , 2019, Front. Aging Neurosci..
[13] Alan C. Evans,et al. Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET , 2019, Front. Aging Neurosci..
[14] J. Kessler,et al. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease , 2019, Annals of neurology.
[15] William J. Jagust,et al. Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span , 2019, The Journal of Nuclear Medicine.
[16] Michael D. Greicius,et al. A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward , 2019, Neuron.
[17] K. Bötzel,et al. [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy , 2018, Front. Aging Neurosci..
[18] D. Na,et al. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease , 2017, Neurobiology of Aging.
[19] D. Na,et al. [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia , 2017, Alzheimer disease and associated disorders.
[20] Daniel R. Schonhaut,et al. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease , 2017, NeuroImage: Clinical.
[21] H. Arai,et al. Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease , 2017, The Journal of Nuclear Medicine.
[22] Rik Ossenkoppele,et al. Distinct 18F‐AV‐1451 tau PET retention patterns in early‐ and late‐onset Alzheimer's disease , 2017, Brain : a journal of neurology.
[23] Hanna Cho,et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease , 2017, Neurobiology of Aging.
[24] S. Gauthier,et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.
[25] C. Rowe,et al. Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy , 2017, European journal of neurology.
[26] W. Jagust,et al. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351 , 2016, PloS one.
[27] Ciprian Catana,et al. Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging , 2016, NeuroImage.
[28] D. Bennett,et al. Association of APOE with tau-tangle pathology with and without β-amyloid , 2016, Neurobiology of Aging.
[29] P. Scheltens,et al. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains , 2015, European Neuropsychopharmacology.
[30] Sang Won Seo,et al. Anatomical heterogeneity of Alzheimer disease , 2014, Neurology.
[31] Lennart Thurfjell,et al. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.
[32] Kazuhiko Yanai,et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.
[33] Bruce R. Rosen,et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data , 2014, NeuroImage.
[34] R. Petersen,et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.
[35] B. Hyman,et al. Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.
[36] Nick C Fox,et al. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele , 2011, The Lancet Neurology.
[37] D. Holtzman,et al. The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.
[38] Steven Warach,et al. Cerebral Microbleeds : A Field Guide to their Detection and Interpretation , 2012 .
[39] Ramon Casanova,et al. Biological parametric mapping: A statistical toolbox for multimodality brain image analysis , 2007, NeuroImage.
[40] D. Neary,et al. Apolipoprotein E ε4 Allele Frequency and Age at Onset of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.
[41] K. Ishii,et al. The effect of APOE &egr;4 allele on cerebral glucose metabolism in AD is a function of age at onset , 2002, Neurology.
[42] K. Welsh-Bohmer,et al. APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.
[43] B T Hyman,et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.
[44] S. Gauthier,et al. Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.
[45] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[46] Jong Min Lee,et al. The Impact of APOE ɛ4 in Alzheimer's Disease Differs According to Age. , 2018, Journal of Alzheimer's disease : JAD.
[47] Sang Won Seo,et al. Amyloid deposition in early onset versus late onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[48] A. Roses,et al. Apolipoprotein E and Alzheimer's disease. , 1996, Annual review of neuroscience.
[49] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .